Pulmonary<i>Mycobacterium abscessus</i>infection treated in combination with inhaled tigecycline

Pedersen, Andreas Arnholdt; Fløe, Andreas; Løkke, Anders; Hilberg, Ole

doi:10.1136/bcr-2023-255383

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to note that linezolid and clarithromycin were used in prior antimicrobial combinations without culture conversion. The main adverse effects documented were aphthous stomatitis and nausea [ 47 ]. There are no reports of use of inhaled tigecycline used in LT patients.…”

Section: Novel Therapiesmentioning

confidence: 99%

Therapy of Mycobacterium abscessus Infections in Solid Organ Transplant Patients

Osman,

Lopez,

Natori

et al. 2024

Microorganisms

View full text Add to dashboard Cite

Mycobacterium abscessus complex (MABC), a rapidly growing Mycobacterium, is one of the most common causes of non-tuberculous mycobacteria (NTM) infections in the United States of America, and it has been associated with a wide spectrum of infections in immunocompetent and immunosuppressed individuals. Eradicating MABC is very challenging, even with prolonged combination therapies. The management of MABC infections in solid organ transplant (SOT) patients is usually complex given their net state of immunosuppression, associated comorbidities, and potential drug–drug interactions, among other things. In this manuscript, we discussed the antimicrobial management of pulmonary and extrapulmonary MABC infections. In addition, we reviewed promising novel therapies such as clofazimine, omadacycline, bedaquiline, and inhaled tigecycline that could join the existing antimicrobial armamentarium to fight this infection associated with significant morbidity and mortality. However, further studies are needed, especially among the immunocompromised host.

show abstract

Section: Novel Therapiesmentioning

confidence: 99%